Skip to main content
SpringerLink
Log in

Targeting Liposomes to Immune Cells

  • Chapter
  • First Online:
Biomaterials in Regenerative Medicine and the Immune System

  • 1102 Accesses

Abstract

Dendritic cells (DCs) are attractive targets for therapies aimed at enhancing or diminishing immunity. The delivery of antigens to DCs can effectively modify antigen-specific T cell responses and provides a strategy for enhancing vaccines which require potent T cell responses. Furthermore, in the absence of adjuvant delivery of antigen to DCs induces antigen-specific T cell anergy, providing a potential method for treating autoimmune diseases. Encapsulation of cargoes including antigens and adjuvants into nanoparticles (NPs) provides a promising method for in situ delivery to DCs. However, DCs are heterogeneous and their subsets mediate disparate functions. Therefore, to achieve effective T cell responses, the design of any NP platform must take into account which DC subset(s) needs to be targeted. In this chapter, we discuss how the function of DC subsets differ, how this impacts NP design, and outline recent promising novel NP platforms that may be suitable for DC targeting.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Morse MA, Chapman R, Powderly J, et al. Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients. Clin Cancer Res. 2011;17(14):4844–53.

    Article  Google Scholar 

  2. Villadangos JA, Young L. Antigen-presentation properties of plasmacytoid dendritic cells. Immunity. 2008;29(3):352–61.

    Article  Google Scholar 

  3. Miller JC, Brown BD, Shay T, et al. Deciphering the transcriptional network of the dendritic cell lineage. Nat Immunol. 2012;13(9):888–99.

    Article  Google Scholar 

  4. Steinman RM, Idoyaga J. Features of the dendritic cell lineage. Immunol Rev. 2010;234(1):5–17.

    Article  Google Scholar 

  5. Hashimoto D, Miller J, Merad M. Dendritic cell and macrophage heterogeneity in vivo. Immunity. 2011;35(3):323–35.

    Article  Google Scholar 

  6. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med. 2002;196(12):1627–38.

    Article  Google Scholar 

  7. Hawiger D, Inaba K, Dorsett Y, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med. 2001;194(6):769–79.

    Article  Google Scholar 

  8. Dudziak D, Kamphorst AO, Heidkamp GF, et al. Differential antigen processing by dendritic cell subsets in vivo. Science. 2007;315(5808):107–11.

    Article  Google Scholar 

  9. Savina A, Peres A, Cebrian I, et al. The small GTPase Rac2 controls phagosomal alkalinization and antigen crosspresentation selectively in CD8(+) dendritic cells. Immunity. 2009;30(4):544–55.

    Article  Google Scholar 

  10. Segura E, Amigorena S. Cross-presentation by human dendritic cell subsets. Immunol Lett. 2014;158(1–2):73–8.

    Article  Google Scholar 

  11. Segura E, Durand M, Amigorena S. Similar antigen cross-presentation capacity and phagocytic functions in all freshly isolated human lymphoid organ-resident dendritic cells. J Exp Med. 2013;210(5):1035–47.

    Article  Google Scholar 

  12. Chatterjee B, Smed-Sorensen A, Cohn L, et al. Internalization and endosomal degradation of receptor-bound antigens regulate the efficiency of cross presentation by human dendritic cells. Blood. 2012;120(10):2011–20.

    Article  Google Scholar 

  13. Cohn L, Chatterjee B, Esselborn F, et al. Antigen delivery to early endosomes eliminates the superiority of human blood BDCA3+ dendritic cells at cross presentation. J Exp Med. 2013;210(5):1049–63.

    Article  Google Scholar 

  14. Mukhopadhaya A, Hanafusa T, Jarchum I, et al. Selective delivery of beta cell antigen to dendritic cells in vivo leads to deletion and tolerance of autoreactive CD8+ T cells in NOD mice. Proc Natl Acad Sci U S A. 2008;105(17):6374–9.

    Article  Google Scholar 

  15. Ring S, Maas M, Nettelbeck DM, Enk AH, Mahnke K. Targeting of autoantigens to DEC205(+) dendritic cells in vivo suppresses experimental allergic encephalomyelitis in mice. J Immunol. 2013;191(6):2938–47.

    Article  Google Scholar 

  16. Yamazaki S, Iyoda T, Tarbell K, et al. Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J Exp Med. 2003;198(2):235–47.

    Article  Google Scholar 

  17. Yamazaki S, Dudziak D, Heidkamp GF, et al. CD8+ CD205+ splenic dendritic cells are specialized to induce Foxp3+ regulatory T cells. J Immunol. 2008;181(10):6923–33.

    Article  Google Scholar 

  18. Kortylewski M, Swiderski P, Herrmann A, et al. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol. 2009;27(10):925–32.

    Article  Google Scholar 

  19. Zhang Q, Hossain DM, Nechaev S, et al. TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo. Blood. 2013;121(8):1304–15.

    Article  Google Scholar 

  20. Caminschi I, Meuter S, Heath WR. DEC-205 is a cell surface receptor for CpG oligonucleotides. Oncoimmunology. 2013;2(3):e23128.

    Article  Google Scholar 

  21. Lahoud MH, Ahmet F, Zhang JG, et al. DEC-205 is a cell surface receptor for CpG oligonucleotides. Proc Natl Acad Sci U S A. 2012;109(40):16270–5.

    Article  Google Scholar 

  22. Zheng X, Vladau C, Zhang X, et al. A novel in vivo siRNA delivery system specifically targeting dendritic cells and silencing CD40 genes for immunomodulation. Blood. 2009;113(12):2646–54.

    Article  Google Scholar 

  23. Basha G, Novobrantseva TI, Rosin N, et al. Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells. Mol Ther. 2011;19(12):2186–200.

    Article  Google Scholar 

  24. Kasturi SP, Skountzou I, Albrecht RA, et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature. 2011;470(7335):543–7.

    Article  Google Scholar 

  25. Speiser DE, Schwarz K, Baumgaertner P, et al. Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. J Immunother. 2010;33(8):848–58.

    Article  Google Scholar 

  26. Ali OA, Emerich D, Dranoff G, Mooney DJ. In situ regulation of DC subsets and T cells mediates tumor regression in mice. Sci Transl Med. 2009;1(8):8ra19.

    Google Scholar 

  27. Ali OA, Verbeke C, Johnson C, et al. Identification of immune factors regulating antitumor immunity using polymeric vaccines with multiple adjuvants. Cancer Res. 2014;74(6):1670–81.

    Article  Google Scholar 

  28. Blander JM, Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature. 2006;440(7085):808–12.

    Article  Google Scholar 

  29. Kratky W, Reis e Sousa C, Oxenius A, Sporri R. Direct activation of antigen-presenting cells is required for CD8+ T-cell priming and tumor vaccination. Proc Natl Acad Sci U S A. 2011;108(42):17414–9.

    Article  Google Scholar 

  30. Bourquin C, Anz D, Zwiorek K, et al. Targeting CpG oligonucleotides to the lymph node by nanoparticles elicits efficient antitumoral immunity. J Immunol. 2008;181(5):2990–8.

    Article  Google Scholar 

  31. Ronaghy A, Prakken BJ, Takabayashi K, et al. Immunostimulatory DNA sequences influence the course of adjuvant arthritis. J Immunol. 2002;168(1):51–6.

    Article  Google Scholar 

  32. Hamdy S, Haddadi A, Hung RW, Lavasanifar A. Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. Adv Drug Deliv Rev. 2011;63(10–11):943–55.

    Article  Google Scholar 

  33. Uto T, Wang X, Sato K, et al. Targeting of antigen to dendritic cells with poly(gamma-glutamic acid) nanoparticles induces antigen-specific humoral and cellular immunity. J Immunol. 2007;178(5):2979–86.

    Article  Google Scholar 

  34. Akagi T, Wang X, Uto T, Baba M, Akashi M. Protein direct delivery to dendritic cells using nanoparticles based on amphiphilic poly(amino acid) derivatives. Biomaterials. 2007;28(23):3427–36.

    Article  Google Scholar 

  35. Uto T, Akagi T, Yoshinaga K, Toyama M, Akashi M, Baba M. The induction of innate and adaptive immunity by biodegradable poly(gamma-glutamic acid) nanoparticles via a TLR4 and MyD88 signaling pathway. Biomaterials. 2011;32(22):5206–12.

    Article  Google Scholar 

  36. Prego C, Paolicelli P, Diaz B, et al. Chitosan-based nanoparticles for improving immunization against hepatitis B infection. Vaccine. 2010;28(14):2607–14.

    Article  Google Scholar 

  37. Arca HC, Gunbeyaz M, Senel S. Chitosan-based systems for the delivery of vaccine antigens. Expert Rev Vaccines. 2009;8(7):937–53.

    Article  Google Scholar 

  38. Schwendener RA. Liposomes as vaccine delivery systems: a review of the recent advances. Ther Adv Vaccines. 2014;2(6):159–82.

    Article  Google Scholar 

  39. Kallen KJ, Heidenreich R, Schnee M, et al. A novel, disruptive vaccination technology: self-adjuvanted RNActive((R)) vaccines. Hum Vacc Immunother. 2013;9(10):2263–76.

    Article  Google Scholar 

  40. Blank F, Stumbles PA, Seydoux E, et al. Size-dependent uptake of particles by pulmonary antigen-presenting cell populations and trafficking to regional lymph nodes. Am J Resp Cell Mol Biol. 2013;49(1):67–77.

    Article  Google Scholar 

  41. Hardy CL, Lemasurier JS, Mohamud R, et al. Differential uptake of nanoparticles and microparticles by pulmonary APC subsets induces discrete immunological imprints. J Immunol. 2013;191(10):5278–90.

    Article  Google Scholar 

  42. Fifis T, Gamvrellis A, Crimeen-Irwin B, et al. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol. 2004;173(5):3148–54.

    Article  Google Scholar 

  43. Foged C, Brodin B, Frokjaer S, Sundblad A. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int J Pharm. 2005;298(2):315–22.

    Article  Google Scholar 

  44. Foged C, Arigita C, Sundblad A, Jiskoot W, Storm G, Frokjaer S. Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition. Vaccine. 2004;22(15–16):1903–13.

    Article  Google Scholar 

  45. Zuhorn IS, Engberts JBFN, Hoekstra D. Gene delivery by cationic lipid vectors: overcoming cellular barriers. Eur Biophys J Biophy. 2007;36(4–5):349–62.

    Article  Google Scholar 

  46. Lv H, Zhang S, Wang B, Cui S, Yan J. Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release. 2006;114(1):100–9.

    Article  Google Scholar 

  47. Ishida T, Harashima H, Kiwada H. Liposome clearance. Biosci Rep. 2002;22(2):197–224.

    Article  Google Scholar 

  48. Idoyaga J, Lubkin A, Fiorese C, et al. Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A. Proc Natl Acad Sci U S A. 2011;108(6):2384–9.

    Article  Google Scholar 

  49. van Broekhoven CL, Parish CR, Demangel C, Britton WJ, Altin JG. Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy. Cancer Res. 2004;64(12):4357–65.

    Article  Google Scholar 

  50. Wengerter BC, Katakowski JA, Rosenberg JM, et al. Aptamer-targeted antigen delivery. Mol Ther. 2014;22(7):1375–87.

    Article  Google Scholar 

  51. Kelly C, Jefferies C, Cryan SA. Targeted liposomal drug delivery to monocytes and macrophages. J Drug Deliv. 2011;2011:727241.

    Article  Google Scholar 

  52. Unger WW, van Beelen AJ, Bruijns SC, et al. Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells. J Control Release. 2012;160(1):88–95.

    Article  Google Scholar 

  53. Kreutz M, Giquel B, Hu Q, et al. Antibody-antigen-adjuvant conjugates enable co-delivery of antigen and adjuvant to dendritic cells in cis but only have partial targeting specificity. PLoS One. 2012;7(7):e40208.

    Article  Google Scholar 

  54. Tam YY, Chen S, Cullis PR. Advances in lipid nanoparticles for siRNA delivery. Pharmaceutics. 2013;5(3):498–507.

    Article  Google Scholar 

  55. Jayaraman M, Ansell SM, Mui BL, et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Ed Engl. 2012;51(34):8529–33.

    Article  Google Scholar 

  56. Semple SC, Akinc A, Chen J, et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol. 2010;28(2):172–6.

    Article  Google Scholar 

  57. Novobrantseva TI, Borodovsky A, Wong J, et al. Systemic RNAi-mediated gene silencing in nonhuman primate and rodent myeloid cells. Mol Ther Nucleic Acids. 2012;1:e4.

    Article  Google Scholar 

  58. Geall AJ, Verma A, Otten GR, et al. Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A. 2012;109(36):14604–9.

    Article  Google Scholar 

  59. Moon JJ, Suh H, Bershteyn A, et al. Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nat Mater. 2011;10(3):243–51.

    Article  Google Scholar 

  60. Moon JJ, Suh H, Li AV, Ockenhouse CF, Yadava A, Irvine DJ. Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction. Proc Natl Acad Sci U S A. 2012;109(4):1080–5.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Microbiology and Immunology, Albert Einstein College of Medicine, 1300 Morris Park Ave, Bronx, NY, 10461, USA

    Dr. Deborah Palliser

  2. Department of Biochemistry, Albert Einstein College of Medicine, 1300 Morris Park Ave, Bronx, 10461, NY, USA

    Dr. Matthew Levy

Authors
  1. Dr. Matthew Levy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dr. Deborah Palliser
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Deborah Palliser .

Editor information

Editors and Affiliations

  1. Albert Einstein College of Medicine, Bronx, New York, USA

    Laura Santambrogio

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Levy, M., Palliser, D. (2015). Targeting Liposomes to Immune Cells. In: Santambrogio, L. (eds) Biomaterials in Regenerative Medicine and the Immune System. Springer, Cham. https://doi.org/10.1007/978-3-319-18045-8_11

Download citation

Publish with us

Policies and ethics

Search

Navigation